NCT01972776View on ClinicalTrials.gov

A Safety, Tolerability and Efficacy Study in Chronic Obstructive Pulmonary Disease (COPD) Patients With QBM076.

PHASE2TerminatedINTERVENTIONAL
Enrollment

48

Participants

Timeline

Start Date

November 30, 2013

Primary Completion Date

May 31, 2015

Study Completion Date

May 31, 2015

Conditions
COPD
Interventions
DRUG

QBM076

Supplied in 25 mg and 75 mg capsules

DRUG

Placebo

Matching placebo capsules

Trial Locations (7)

10117

Novartis Investigative Site, Berlin

22947

Novartis Investigative Site, Großhansdorf

23225

Novartis Investigative Site, Richmond

30625

Novartis Investigative Site, Hanover

60596

Novartis Investigative Site, Frankfurt

Sector 5

Novartis Investigative Site, Bucharest

M23 9QZ

Novartis Investigative Site, Manchester

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY